Compare · MCRB vs STOK
MCRB vs STOK
Side-by-side comparison of Seres Therapeutics Inc. (MCRB) and Stoke Therapeutics Inc. (STOK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MCRB and STOK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- STOK is the larger of the two at $2.16B, about 43.0x MCRB ($50.2M).
- STOK has been more active in the news (15 items in the past 4 weeks vs 11 for MCRB).
- STOK has more recent analyst coverage (18 ratings vs 10 for MCRB).
- Company
- Seres Therapeutics Inc.
- Stoke Therapeutics Inc.
- Price
- -
- -
- Market cap
- $50.2M
- $2.16B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2019
- News (4w)
- 11
- 15
- Recent ratings
- 10
- 18
Seres Therapeutics Inc.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Stoke Therapeutics Inc.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Latest MCRB
- SEC Form EFFECT filed by Seres Therapeutics Inc.
- Officer Brady Kelly sold $291 worth of shares (64 units at $4.55) as part of a pre-agreed trading plan and converted options into 181 shares, increasing direct ownership by 1% to 8,679 units (SEC Form 4)
- Director Shaff Eric D. converted options into 722 shares and sold $1,197 worth of shares (263 units at $4.55) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 12,499 units (SEC Form 4)
- Officer Henn Matthew R converted options into 238 shares and sold $369 worth of shares (81 units at $4.55) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 7,995 units (SEC Form 4)
- Officer Desrosier Thomas sold $373 worth of shares (82 units at $4.55) as part of a pre-agreed trading plan and converted options into 245 shares, increasing direct ownership by 2% to 8,117 units (SEC Form 4)
- SEC Form S-3 filed by Seres Therapeutics Inc.
- SEC Form 10-Q filed by Seres Therapeutics Inc.
- Seres Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
- Seres Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
Latest STOK
- Analyst resumed coverage on Stoke Therapeutics with a new price target
- CHIEF MEDICAL OFFICER Ticho Barry converted options into 10,000 shares and sold $152,690 worth of shares (4,767 units at $32.03), increasing direct ownership by 26% to 25,655 units (SEC Form 4) to satisfy withholding tax
- Director Kaye Edward M. Md converted options into 26,250 shares and sold $402,528 worth of shares (12,567 units at $32.03), increasing direct ownership by 12% to 124,557 units (SEC Form 4) to satisfy withholding obligation
- GENERAL COUNSEL & CORP SEC Allan Jonathan converted options into 6,000 shares and sold $91,639 worth of shares (2,861 units at $32.03), increasing direct ownership by 17% to 21,225 units (SEC Form 4) (tax withholding)
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.
- CHIEF MEDICAL OFFICER Ticho Barry sold $208,385 worth of shares (7,176 units at $29.04) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 20,422 units (SEC Form 4)
- Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
- SEC Form 8-K filed by Stoke Therapeutics Inc.